Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2023-07-06 Director's Dealing
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2023-07-06 English
Regulatory Filings 2023
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but without meaningful content, it cannot be classified as a financial or corporate report.
2023-07-05 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering. It includes a prospectus describing the securities to be sold by selling securityholders. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and offering. This fits the category of Capital/Financing Update (CAP), as it provides information about the registration and potential sale of shares by selling securityholders. The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2023-06-28 English
4
Director's Dealing
2023-06-26 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2023, reporting the submission of matters to a vote of security holders at the company's Annual Meeting of Stockholders. It includes detailed voting results for director elections and ratification of the independent auditor. The content focuses on the official results of shareholder votes at the AGM. The document length is 3923 characters, which is relatively short but contains substantive voting results, not just an announcement of a report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-06-15 English
SC 13G
Major Shareholding Notification
2023-06-12 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.